Eli Lilly to Acquire AtaiBeckley for up to $3.8 Billion, Entering Psychedelic Drug Market

Eli Lilly announced on Thursday it will acquire AtaiBeckley in a deal valued at up to $3.8 billion, a major strategic move that brings the pharmaceutical giant into the growing field of psychedelic-based treatments for mental health disorders.

Deal Structure and Terms

Under the terms of the agreement, Eli Lilly will pay $6.75 per share in cash for AtaiBeckley, representing a premium of approximately 26% to the stock’s closing price on Wednesday. The transaction consists of a $2.8 billion upfront payment with up to an additional $1 billion contingent on achieving certain development and regulatory milestones.

Following the announcement, shares of AtaiBeckley surged more than 30% in premarket trading. The companies anticipate the acquisition will close in the third quarter, according to the official statement.

Strategic Rationale

The acquisition gives Lilly control of AtaiBeckley's lead drug candidate, BPL-003, a psychedelic-based nasal spray currently in late-stage development. The therapy is being evaluated for treatment-resistant depression, a severe form of the condition that does not respond to standard treatments.

Ad

"Millions of people are still searching for relief and desperately need a therapy that works," said Carole Ho, president of Lilly Neuroscience. This deal is Lilly's latest investment in its neuroscience pipeline, following its up to $7.8 billion purchase of Centessa Pharmaceuticals in June to acquire experimental drugs for sleep-wakefulness regulation.

Industry Context

Lilly's move reflects a broader industry trend of major drugmakers exploring psychedelic compounds for psychiatric conditions. Last year, AbbVie acquired an experimental depression drug from Gilgamesh Pharmaceuticals in a deal worth up to $1.2 billion. The sector has also seen increased U.S. federal funding and calls from regulators for accelerated reviews.

Analysts note the deal helps Lilly diversify its portfolio beyond its highly successful cardiometabolic franchise, which includes blockbuster obesity drugs. BMO analyst Evan Seigerman stated the acquisition "would provide differentiated exposure in psychiatry" and supports Lilly's strategy of using cash from its current top-sellers to strengthen its future drug pipeline.